SOPHIA GENETICS SA |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 4.6 EUR | +0.88% |
|
+6.48% | +6.48% |
| 05-29 | Sector Update: Health Care Stocks Fall Late Afternoon | MT |
| 05-29 | Sophia Genetics Rallies Wednesday after Partnering with Microsoft, Nvidia on Whole Genome Analytics Platform | MT |
| Sales 2024 * | 78.86M 72.72M 6.19B | Sales 2025 * | 101M 93.37M 7.95B | Capitalization | 326M 301M 25.6B |
|---|---|---|---|---|---|
| Net income 2024 * | -62M -57.17M -4.87B | Net income 2025 * | -54M -49.79M -4.24B | EV / Sales 2024 * | 3.43 x |
| Net cash position 2024 * | 55.96M 51.6M 4.39B | Net cash position 2025 * | 8.9M 8.21M 698M | EV / Sales 2025 * | 3.13 x |
| P/E ratio 2024 * |
-5.22
x | P/E ratio 2025 * |
-6.01
x | Employees | 430 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 79.99% |
More Fundamentals
* Assessed data
More news
Latest transcript on SOPHiA GENETICS SA
More recommendations
More press releases
More news
| 1 day | +0.88% | ||
| 1 week | +6.48% | ||
| 1 month | -1.29% | ||
| 3 months | +1.77% | ||
| 6 months | +26.37% | ||
| Current year | +6.48% |
1 week
4.30
4.60
1 month
4.124.68
Current year
3.725.10
1 year
2.985.10
3 years
2.985.10
5 years
2.985.10
10 years
2.985.10
| Managers | Title | Age | Since |
|---|---|---|---|
Jurgi Camblong
FOU | Founder | 45 | 31/12/10 |
Ross Muken
DFI | Director of Finance/CFO | 44 | 31/01/21 |
Abhimanyu Verma
CTO | Chief Tech/Sci/R&D Officer | - | 09/01/22 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Didier Hirsch
BRD | Director/Board Member | 72 | 31/05/20 |
Vincent Ossipow
BRD | Director/Board Member | 55 | 31/05/14 |
Kathy Hibbs
BRD | Director/Board Member | 60 | 28/02/21 |
| Date | Price | Change |
|---|---|---|
| 31/05/24 | 4.6 | +0.88% |
| 30/05/24 | 4.56 | +2.70% |
| 29/05/24 | 4.44 | +3.26% |
| 28/05/24 | 4.3 | -0.46% |
| 27/05/24 | 4.32 | -.--% |
Delayed Quote Deutsche Boerse AG, May 31, 2024 at 07:03 am
More quotes
Sophia Genetics SA is a Switzerland-based company engaged in the software publishing sector. The Company offer a cloud-based Software-as-a-Service platform - the SOPHiA DDM, which is data-driven medicine platform enabling insights from disparate, complex datasets to improve diagnosis, treatment, and drug development. The Company has offices in Switzerland, France and the United Kingdom and operates worldwide.
Sector
Software
Calendar
05/08/2024
- Q2 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
4.99
USD
Average target price
8.667
USD
Spread / Average Target
+73.68%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +10.52% | 3,085B | |
| +8.91% | 85.92B | |
| +5.14% | 77.91B | |
| -16.20% | 52.89B | |
| +26.18% | 48.28B | |
| +28.93% | 45.38B | |
| -34.05% | 40.83B | |
| +66.72% | 38.78B | |
| -0.36% | 27.48B |
- Stock Market
- Equities
- SOPH Stock
- 90B Stock
